You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
舒泰神(300204.SZ)擬與昭衍新藥簽署銷售框架協議和研發服務框架協議
格隆匯 02-09 19:02

格隆匯 2 月 9日丨舒泰神(300204.SZ)公佈,根據公司業務發展的需求,公司擬與關聯方北京昭衍新藥研究中心股份有限公司(“昭衍新藥”)簽署《銷售框架協議》和《研發服務框架協議》。公司與昭衍新藥的實際控制人為周志文和馮宇霞,故此次交易構成關聯交易。

根據擬簽署的《銷售框架協議》和《研發服務框架協議》,公司將向關聯方昭衍新藥及其子公司採購主要產品蘇肽生的原材料小鼠頜下腺,預計2021年和2022年的採購金額上限分別為150萬元和150萬元;公司將接受關聯方昭衍新藥及其子公司提供的醫藥研發技術服務,預計2021年和2022年的服務金額上限分別為6000萬元和7000萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account